ERBBal Remedies: Combination Therapy for EGFR-mutant Lung Cancers

Multiple members of the ERBB/HER family of the receptor tyrosine kinases have been implicated in mediating acquired resistance to EGFR inhibitors that are used to treat EGFR-mutant lung cancers. New single agents and combination therapies targeting the ERBB/HER family members are being investigated to either prevent or overcome the emergence of acquired resistance. Clin Cancer Res; 24(22); 5499–501. ©2018 AACR.

See related article by Romaniello et al., p. 5610

https://ift.tt/2DET73r